All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in myelofibrosis. The session was chaired by John Mascarenhas and involved an analysis from Claire Harrison, Haifa Kathrin Al-Ali, Tiziano Barbui, Jean-Jacques Kiladjian, and Stefan N. Constantinescu.
The future of JAK inhibition in myelofibrosis
Key topics of discussion included: “How to select appropriate JAK inhibitors in patients with myelofibrosis (MF)”; “What patient subsets a JAK inhibitor may capture”; and “The future of JAK inhibitors in treating myelofibrosis, and whether this type of inhibitor will exist as a single agent or in combination therapy at initiation.
ASH 2020 | Practice-changing abstracts in myeloproliferative neoplasms
The world-leading experts in MPN shared the top abstracts from ASH 2020 that they believe could have the greatest impact on clinical practice.
What effect does idasanutlin have on TP53-mutated clones in patients with polycythemia vera?
The MPN Hub were pleased to speak to Jean-Jacques Kiladjian during ASH 2019. We asked: What effect does idasanutlin have on TP53-mutated clones in patients...
Subscribe to get the best content related to MPN delivered to your inbox